Washington, D.C. 20549

                                  FORM 8-K

                               CURRENT REPORT
                   Pursuant to Section 13 or 15(d) of the
                      Securities Exchange Act of 1934

 Date of Report (Date of Earliest Event Reported): September 5, 2001
                                                   (September 4, 2001)

           (Exact name of registrant as specified in its charter)

DELAWARE                            39040                       13-4022871
(State or other            (Commission File Number)          (I.R.S. Employer
jurisdiction of                                             Identification No.)

100 Painters Drive
Chadds Ford, Pennsylvania                                           19317
(Address of principal executive offices)                         (Zip Code)

                               (610) 558-9800
            (Registrant's telephone number, including area code)

       (Former name or former address, if changed since last report)

Item 5.           Other Events.

                  On September 4, 2001, the Registrant issued a press
release, a copy of which is filed herewith as Exhibit 99.1 and is
incorporated herein by reference.

Item 7.           Financial Statements and Exhibits.

(a)      Financial Statements of Business Acquired.

                  Not applicable

(b)      Pro Forma Financial Information.

                  Not applicable.

(c)      Exhibits.

Exhibit Number             Description

99.1                       Press release issued by Endo Pharmaceuticals
                           Holdings Inc. on September 4, 2001


         Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized.

                                    ENDO PHARMACEUTICALS HOLDINGS INC.

                                    By: /S/  CAROL A. AMMON
                                        Name:  Carol A. Ammon
                                        Title: President & Chief Executive

Dated:  September 5, 2001

                             INDEX TO EXHIBITS

Exhibit No.                 Description

99.1               Press release issued by Endo Pharmaceuticals Holdings Inc.
                   on September 4, 2001

                                                               Exhibit 99.1

Contact: Robert Siegfried/Jeremy Fielding
Kekst and Company

                  EXTENDED-RELEASE TABLETS, 80 mg) PATENTS

         Chadds Ford, PA, September 4, 2001 - Endo Pharmaceuticals Holdings
Inc. (NASDAQ: ENDP and ENDPW), a fully integrated, specialty pharmaceutical
company with market leadership in pain management, announced today that, on
August 30, 2001, The Purdue Frederick Company (and related companies,
"Purdue") filed suit against Endo Pharmaceuticals Holdings Inc. and its
subsidiary, Endo Pharmaceuticals Inc., in the U.S. District Court for the
Southern District of New York alleging that Endo Pharmaceuticals Inc.'s
bioequivalent version of Purdue's OxyContin(R), 80 mg strength, infringes
three of its patents. This is the third suit filed by Purdue against Endo
relating to Endo Pharmaceuticals Inc.'s bioequivalent versions of Purdue's

         The first suit was filed on October 20, 2000 after Purdue was
informed that the United States Food and Drug Administration (FDA) accepted
Endo Pharmaceuticals Inc.'s Abbreviated New Drug Application (ANDA)
submission, including the required Paragraph IV certification, for a
bioequivalent version of Purdue Frederick's OxyContin(R), 40 mg strength.
The second suit was filed on March 13, 2001 after Purdue was informed that
on February 9, 2001, Endo Pharmaceuticals Inc. amended this ANDA to add
bioequivalent versions of the 10 mg and 20 mg strengths of OxyContin(R). On
July 30, 2001, Endo Pharmaceuticals Inc. amended this ANDA again to add the
bioequivalent version of the 80 mg strength of OxyContin(R), which is the
subject of the third suit.

         OxyContin(R) is indicated for the treatment of moderate-to-severe
pain. Although Endo believes the patents asserted by Purdue are invalid
and/or not infringed, no assurance can be given as to the outcome of the
patent challenge process.

         Carol A. Ammon, Endo's President and Chief Executive Officer,
said, "Endo is very pleased to have amended its ANDA to add the 80 mg
strength of oxycodone hydrochloride extended-release tablets. Endo now has
an ANDA on file with the FDA for every strength of OxyContin(R) presently
available. This litigation with Purdue Frederick highlights Endo's
continued commitment to expanding its portfolio of pain management
products. As with the 10 mg, 20 mg and 40 mg lawsuits, we are prepared to
vigorously defend our position in this litigation."

         Endo, through its wholly owned subsidiaries Endo Pharmaceuticals
Inc. and Endo Inc., is a fully integrated specialty pharmaceutical company
with market leadership in pain management. The company is engaged in the
research, development, sales and marketing of both branded and generic
pharmaceutical products primarily for the treatment of pain. Endo has a
portfolio of thirteen branded products that includes established brands
such as Percocet(R) and Percodan(R), opioid analgesics that treat
moderate-to-severe pain.

         To the extent any statements made in this release contain
information that is not historical, these statements are essentially
forward-looking and are subject to risks and uncertainties. As a result of
such risks and uncertainties, which include, but are not limited to, the
difficulty of predicting FDA approvals, risks with respect to technology
and product development, the effect of competing products and prices,
uncertainties regarding intellectual property protection, uncertainties as
to the outcome of litigation, changes in operating results and other risks
discussed from time to time in Endo's filings with the Securities and
Exchange Commission, actual results may differ materially from those
expressed or implied by such forward-looking statements.

                                   # # #